168 related articles for article (PubMed ID: 31804856)
1. Review of Current Policy Strategies to Reduce US Cancer Drug Costs.
Green AK; Ohn JA; Bach PB
J Clin Oncol; 2020 Feb; 38(4):372-379. PubMed ID: 31804856
[No Abstract] [Full Text] [Related]
2. Overspending driven by oversized single dose vials of cancer drugs.
Bach PB; Conti RM; Muller RJ; Schnorr GC; Saltz LB
BMJ; 2016 Feb; 352():i788. PubMed ID: 26932932
[No Abstract] [Full Text] [Related]
3. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
Low E;
J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
[No Abstract] [Full Text] [Related]
4. Controlling the cost of innovative cancer therapeutics.
Malik NN
Nat Rev Clin Oncol; 2009 Sep; 6(9):550-2. PubMed ID: 19707244
[TBL] [Abstract][Full Text] [Related]
5. Addressing cost-related nonadherence to oral anticancer medications through health policy reform: Challenges and opportunities.
Jazowski SA; Dusetzina SB
Cancer; 2020 Aug; 126(16):3613-3616. PubMed ID: 32438468
[No Abstract] [Full Text] [Related]
6. Can treatment costs be tamed?
Malakoff D
Science; 2011 Mar; 331(6024):1545-7. PubMed ID: 21436438
[No Abstract] [Full Text] [Related]
7. Tackling Cost: A Prescription for Spending Wisely.
Tempero M
J Natl Compr Canc Netw; 2019 Jun; 17(6):633. PubMed ID: 31200360
[No Abstract] [Full Text] [Related]
8. Value in Oncology: It Is in the Eyes of the Beholder.
Nabhan C; Phillips EG; Feinberg BA
J Natl Compr Canc Netw; 2019 Jan; 17(1):2-5. PubMed ID: 30659123
[No Abstract] [Full Text] [Related]
9. The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable.
Prasad V; Mailankody S
Mayo Clin Proc; 2016 Jun; 91(6):707-12. PubMed ID: 27261866
[No Abstract] [Full Text] [Related]
10. Payment for oncolytics in the United States: a history of buy and bill and proposals for reform.
Polite BN; Ward JC; Cox JV; Morton RF; Hennessy J; Page RD; Conti RM
J Oncol Pract; 2014 Nov; 10(6):357-62. PubMed ID: 25398955
[TBL] [Abstract][Full Text] [Related]
11. Targeted immunotherapies overtaking emerging oncology market value based growth.
Jakovljevic MB
J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
[No Abstract] [Full Text] [Related]
12. Health policy: Putting a price on cancer.
Sullivan R; Aggarwal A
Nat Rev Clin Oncol; 2016 Mar; 13(3):137-8. PubMed ID: 26856742
[No Abstract] [Full Text] [Related]
13. Cancer Drugs Fund of minimal benefit.
Burki TK
Lancet Oncol; 2017 Jun; 18(6):e305. PubMed ID: 28483412
[No Abstract] [Full Text] [Related]
14. Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 29117395
[No Abstract] [Full Text] [Related]
15. Patient Financial Assistance Programs: A Path to Affordability or a Barrier to Accessible Cancer Care?
Zafar SY; Peppercorn JM
J Clin Oncol; 2017 Jul; 35(19):2113-2116. PubMed ID: 28459612
[No Abstract] [Full Text] [Related]
16. The drug industry can help reduce cancer drug costs.
Gilbar PJ; Tannock MJ
BMJ; 2016 Mar; 352():i1551. PubMed ID: 27001595
[No Abstract] [Full Text] [Related]
17. Cancer Care Under the Biden Administration.
Dusetzina SB
JAMA; 2021 Feb; 325(6):527-528. PubMed ID: 33560329
[No Abstract] [Full Text] [Related]
18. Obstacles to affordable cancer treatments.
Dusetzina SB; Muluneh B; Khan T; Richards KL; Keating NL
N C Med J; 2014; 75(4):257-60. PubMed ID: 25046090
[TBL] [Abstract][Full Text] [Related]
19. Limits on Medicare's ability to control rising spending on cancer drugs.
Bach PB
N Engl J Med; 2009 Feb; 360(6):626-33. PubMed ID: 19176475
[No Abstract] [Full Text] [Related]
20. Cancer drugs in the United States: Justum Pretium--the just price.
Kantarjian HM; Fojo T; Mathisen M; Zwelling LA
J Clin Oncol; 2013 Oct; 31(28):3600-4. PubMed ID: 23650428
[No Abstract] [Full Text] [Related]
[Next] [New Search]
